PHA-543613,99.95%
产品编号:Bellancom-105670| CAS NO:478149-53-0| 分子式:C15H17N3O2| 分子量:271.31
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
PHA-543613
| 产品介绍 | PHA-543613 是一种有效的、具有口服活性、可穿过血脑屏障和选择性的 α7 nAChR 激动剂,Ki 为 8.8 nM。PHA-543613 对 α7-nAChR 的选择性优于 α3β4、α1β1γδ、α4β2 和 5-HT3 受体。PHA-543613 可用于阿尔茨海默病和精神分裂症的认知缺陷研究。 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 生物活性 | PHA-543613 is a potent, orally active, brain-penetrant and selective α7 nAChR agonist with a Ki of 8.8 nM. PHA-543613 displays selectivity for α7-nAChR over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors. PHA-543613 can be used for the cognitive deficits of Alzheimer's disease and schizophrenia research. | ||||||||||||||||
| 体外研究 | |||||||||||||||||
| 体内研究 |
PHA-543613 (0.3 mg/kg) successfully reverses Scopolamine-induced short-term memory deficits in rats. PHA-543613 (4 and 12 mg/kg; i.p. once) reduces behavioral deficits and brain edema is dependent on the PI3K-Akt signaling pathway. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||
| 体内研究 |
PHA-543613 (0.3 mg/kg) successfully reverses Scopolamine-induced short-term memory deficits in rats. PHA-543613 (4 and 12 mg/kg; i.p. once) reduces behavioral deficits and brain edema is dependent on the PI3K-Akt signaling pathway. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||
| 性状 | Solid | ||||||||||||||||
| 溶解性数据 |
In Vitro:
DMSO : 250 mg/mL (921.46 mM; Need ultrasonic) H2O : 100 mg/mL (368.58 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 | ||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
| 储存方式 |
| ||||||||||||||||
| 参考文献 |
|

浙公网安备 33010802013016号